Gout
Sobi Acquires Arthrosi Therapeutics for $950M Upfront in Gout Drug Deal
Sobi; Arthrosi Therapeutics; acquisition; gout; pozdeutinurad; AR882
Takeda to Discontinue Uloric: A Gradual Decline of the Gout Medication
Takeda, Uloric, gout medication, discontinuation, cardiovascular risks, FDA scrutiny
George Church’s GRObio Secures $60 Million to Advance Gout Treatment into Clinical Trials
GRObio, George Church, Gout Treatment, Clinical Trials, Biotech Funding